Recent studies have shown exceptional responses to neoadjuvant immunotherapy with botensilimab (anti-CTLA-4) and balstilimab (anti-PD-1) for pMMR/MSS colorectal cancer, suggesting another approach to improve tumor regression and restore the TiME [36]. This evidence concerns the gene CTLA4 and neoplasm.